Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

®). She joined the AJMC team in 2021, where she produces written and video content covering multiple disease states.

She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on 

Articles

Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma (CSCC) post-surgery.

Adjuvant Cemiplimab Significantly Improves Disease-Free Survival in High-Risk Skin Cancer

Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.

She has a BA in English language and literature from Rutgers University. You can connect with Julia on 

Women who are using heroin and were recently incarcerated had increased stimulant use, which is associated with adverse outcomes in HIV.

Behavioral, Structural Vulnerabilities in Women With HIV Identified After Recent Incarceration

With emergency evacuation orders requiring swift action, less mobile individuals, such as those with disabilities or the elderly, are often left behind.

Wildfire Evacuations Spell Difficulties for Disabled, Elderly Residents

Cameron Santoro is an associate editor for 

), AJMC.com, and The Center for Biosimilars

The Affordable Care Act (ACA) led to reductions in out-of-pocket costs and improvements in health among adults entering Medicare.

ACA Impact on Medicare Beneficiaries Linked to Reduced Costs, Improved Health

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

MASH

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Exploring Novel Treatment Options for Alopecia Areata

Video Series

Deciding When to Treat Patients With Alopecia Areata

Video content above is prompted by the following:

 In which patients do you treat AA vs use observation? Is there a scoring system that you use?

Videos

Panelists discuss how recent advancements, particularly the introduction of Janus kinase JAK inhibitors, are reshaping the treatment landscape for Aalopecia Aareata, offering new therapeutic options and addressing unmet needs in both efficacy and patient care.

Panelists discuss how alopecia areata (AA) is a chronic autoimmune disease characterized by inflammation that attacks hair follicles, leading to hair loss and varying disease progression.

Discussing the Pathophysiology of Alopecia Areata

Panelists discuss how concurrent comorbidities, such as thyroid disorders and other autoimmune conditions, are commonly seen in patients with alopecia areata (AA) and how they complicate disease management and increase the overall burden on patients.

Common Comorbidities Associated With Alopecia Areata

Panelists discuss how alopecia areata (AA) presents with hallmark symptoms such as sudden hair loss, and how the condition fluctuates over time, making it a relapsing or remitting inflammatory disease.

Hallmark Symptoms Seen With Alopecia Areata

Panelists discuss how ongoing or recurrent hair loss in patients with alopecia areata (AA) leads to significant psychological effects, impacting their mental health, and how different forms of AA may be harder for some patients to cope with, with strategies for managing these psychological challenges in clinical practice.

Psychosocial Impact of Alopecia Areata

Panelists discuss how alopecia areata (AA) is included in the differential diagnosis for hair loss conditions and how a definitive diagnosis is made through clinical evaluation and, when necessary, additional diagnostic tests.

Diagnosis of Alopecia Areata

Panelists discuss how managing alopecia areata (AA) involves multiple health care specialties, including dermatology and mental health, and how multidisciplinary care can be optimized, while also addressing strategies to alleviate financial barriers that patients may face in accessing treatment.

Multimodal Care for Patients With Alopecia Areata

Panelists discuss how the epidemiology of alopecia areata (AA) varies across different patient populations, with certain forms of the disease being more prevalent in specific groups.

Epidemiology Associated wWith Alopecia Areata

Panelists discuss how the decision to treat vs observe alopecia areata (AA) depends on factors such as disease severity, patient symptoms, and the use of scoring systems to guide treatment decisions.

Panelists discuss how key factors such as disease severity, patient preference, and payer requirements influence the choice of initial therapy for alopecia areata (AA), highlighting which drug classes have the highest and lowest success rates.

Choosing an Initial Therapy for Alopecia Areata

Alopecia areata (AA) is a chronic autoimmune disorder characterized by non-scarring hair loss, primarily due to the immune system's attack on hair follicles. The pathophysiology involves a breakdown in immune privilege of hair follicles, leading to an inflammatory response. Cytotoxic T cells, particularly CD8+ T cells, infiltrate the hair follicle, causing hair loss. Inflammation plays a crucial role, with cytokines such as IFN-γ and TNF-α contributing to the immune-mediated destruction of hair follicles. The chronic nature of AA is attributed to persistent immune dysregulation and genetic predisposition.

Deciding When to Treat Patients With Alopecia Areata

EP: 1.Discussing the Pathophysiology of Alopecia Areata

EP: 2.Common Comorbidities Associated With Alopecia Areata

EP: 3.Hallmark Symptoms Seen With Alopecia Areata

EP: 4.Psychosocial Impact of Alopecia Areata

EP: 5.Diagnosis of Alopecia Areata

EP: 6.Multimodal Care for Patients With Alopecia Areata

EP: 7.Epidemiology Associated wWith Alopecia Areata

EP: 8.Deciding When to Treat Patients With Alopecia Areata

EP: 9.Choosing an Initial Therapy for Alopecia Areata